AstraZeneca’s Imfinzi bladder cancer regimen improves survival in Phase III trial
UK-based pharmaceutical company AstraZeneca has reported positive results from the Phase III NIAGARA trial of Imfinzi alongside neoadjuvant chemotherapy. The…
All articles by Vishnu Priya N
Vishnu Priya N
-
-
University of Auckland researchers begin trial to improve safety of 5-fluorouracil
Researchers from the University of Auckland and Auckland City Hospital in New Zealand have begun a clinical trial aiming to…
-
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) trial of its…
-
Contineum concludes enrolment in Phase II multiple sclerosis therapy trial
Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist PIPE-307…
-
Samsung Biologics and LigaChem extend ADC services deal
Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services. The partnership will leverage Samsung Biologics'…
-
Genelux doses first subject in Phase II trial of NSCLC treatment
Genelux has dosed the first subject in the Phase II VIRO-25 clinical trial in the US, designed to assess the…
-
Galderma reports data from Phase III trial of anti-ageing product RelabotulinumtoxinA
Swiss skincare company Galderma has reported positive data from a Phase III clinical trial of RelabotulinumtoxinA (Relfydess) for treating moderate-to-severe…
-
Find Therapeutics dosing subjects in study of FTX-101 for chronic optic neuropathy
Canadian biopharmaceutical company Find Therapeutics has dosed the first subject in a Phase I trial of its lead compound, FTX-101,…
-
Lutris ends subject enrolment in EGFRI-induced acneiform rash trial
Lutris Pharma has concluded subject enrolment in its Phase II clinical trial of LUT014, a new B-Raf inhibitor designed for…
-
Airway Therapeutics to trial drug for bronchopulmonary dysplasia in newborn babies
US-based biotechnology company Airway Therapeutics is to launch a multinational Phase III clinical trial of zelpultide alfa, a drug designed…
